| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
As the main cause of peptic ulcer disease and a major risk factor for gastric cancer, Helicobacter pylori, or H. pylori, requires treatment to prevent life-threatening medical conditions. Timely diagnosis is critical for improving outcomes and avoiding further harm. However, the rising prevalence of antimicrobial resistance presents a clinical challenge to physicians when deciding who to test and the best medication to treat bacterial infection.
4.4 billion
4.4 billion individuals globally are affected by H. pylori infection
35%-85%
35%-85% of children have H. pylori infection depending on their geographic region1,2
Helicobacter pylori Test menu
Our H. pylori assay provides a streamlined solution to the challenge of diagnosing and treating the infection by evaluating for both the bacteria and antimicrobial resistance through one noninvasive test. Especially suited for children, our assay is the only clinically available test of its kind and uses a single stool specimen to predict clarithromycin resistance.
Key testing
Advantages
Highlights
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.
Key testing